Table 51: Patient Characteristics. Transurethral Needle Ablation (TUNA) Versus TURP.
| Study, Year | Patients, No (Treatment, control) | Inclusion criteria | Prostate size Mean (SD), mL | Mean follow-up Years (months where specified) | Equipment and software | No available for follow-up |
|---|---|---|---|---|---|---|
| Hill et al. 2004 (80) | 121 (65, 56) |
Patients with BPH 50 years or older; prostate size 20–75 gr; LUTS ≥3 months; IPSS >13; Qmax ≤12 mL/s; minimum voided volume ≥125 mL | NR | 5 | NR |
5 years IPSS/QOL: TUNA: 18 TURP: 22 Qmax: TUNA: 13 TURP: 15 PVR: TUNA: 13 TURP: 17 |
| Cimentepe et al. 2003 (81) | 59 (26, 33) |
Patients with BPH >40 years old; prostate size >70 gr; IPSS >13’; Qmax <15 mL/s | 46.1 (11.2) 49.1 (17.7) P =.591 |
1.5 | Vidamed® Inc. | NR |
BPH refers to benign prostatic hyperplasia; IPSS, International Prostate Symptom Score; LUTS, Lower urinary tract symptoms; NR, not reported; PVR, postvoid residual urine; Qmax, maximum flow rate; QOL, Quality of life; SD, standard deviation; TUNA; transurethral needle ablation; TURP transurethral resection of the prostate